Skip Navigation


Full-Court Press on COVID-19 Immunology

Full-Court Press on COVID-19 Immunology

The school of medicine and the Johns Hopkins Bloomberg School of Public Health have launched a new center for intensely studying the immune response to SARS-CoV-2 to improve serological tests for the pathogen. The goal is to provide a deeper understanding of the mechanisms by which the virus impacts the immune system in order to facilitate development of effective treatments and vaccines against it.

The joint research project was established under a five-year grant from the National Cancer Institute. The funding of more than $2 million per year supports studies of the immune elements that determine whether people get mild or severe COVID-19 illness following exposure to the virus.

“A lot of researchers have been studying COVID-19 on the side, but with a center grant like this, we can support a full-time focus on it by multiple investigators working as a team, and that gives us a good chance to solve some of the outstanding mysteries about this disease,” says Professor of Medicine Andrea Cox, who is co-leading JH-EPICS (the Johns Hopkins Excellence in Pathogenesis and Immunity Center for SARS-CoV-2) together with Sabra Klein, professor of molecular microbiology and immunology at the Bloomberg School.

“Our new center’s goal is to combine Johns Hopkins’ world-class expertise in immunology, virology and biostatistics to map out the complexity of the immune response as it develops after infection — and to understand why that response can differ so greatly depending on age, gender, race, comorbidities such as obesity, and other factors,” Klein says.

Research at the center will focus on several immunological aspects of the novel coronavirus and COVID-19, including antibody- and cell-driven immunity, immune genetics, autoimmunity, molecular virology and other relevant fields.

The center’s researchers will be able to draw upon the clinical resources of Johns Hopkins Medicine, including thousands of blood samples taken from COVID-19 patients at all stages of infection. Additionally, the advanced quantitative techniques of computational biologists and biostatisticians at the Bloomberg School will help define meaningful patterns from enormous amounts of data.

back to top button